# A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia

> **NCT02627677** · PHASE3 · TERMINATED · sponsor: **Ariad Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Chronic Phase Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Ponatinib 30 mg QD
- **DRUG:** Ponatinib 15 mg QD
- **DRUG:** Nilotinib 400 mg BID

## Key facts

- **NCT ID:** NCT02627677
- **Lead sponsor:** Ariad Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-31
- **Primary completion:** 2020-10-29
- **Final completion:** 2021-01-20
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** The study was stopped due to operational feasibility and not due to any safety concerns
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02627677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02627677, "A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02627677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*